

Wright Medical Group, Inc.
Pro Forma Sales Growth Information
(unaudited)

Third Quarter 2014
Pro Forma
Constant Currency Sales
Growth ⁽¹⁾

U.S.	
Foot and Ankle	12%
Upper Extremity	(7%)
Biologics	(4%)
Other	26%
Total U.S.	6%
International	
Foot and Ankle	10%
Upper Extremity	13%
Biologics	29%
Other	(4%)
Total International	14%
Global	
Foot and Ankle	11%
Upper Extremity	(1%)
Biologics	5%
Other	2%
Total Sales	8%

(1) Pro Forma Constant Currency Sales Growth is calculated as the growth of 2014 actual sales, excluding the impact of foreign currency over 2013 pro forma sales (as defined and reconciled below).

Wright Medical Group, Inc.
Pro Forma Same Day Sales Growth Information
(unaudited)

Third Quarter 2014
Pro Forma
Same Day
Sales Growth ⁽¹⁾

U.S.	
Foot and Ankle	12%
Upper Extremity	(7%)
Biologics	(4%)
Other	26%
Total U.S.	6%

Pro Forma Same Day Sales Growth is calculated as the growth of 2014 sales per selling day over 2013 pro forma sales (as defined and reconciled below) per selling day. We provide the number of U.S. selling days per quarter on our website at “Corporate - Investor Information - Financial Information - U.S. Selling Days.”

Wright Medical Group, Inc.
Pro Forma Sales
(unaudited)

	Q3 2013		
	As Reported	Acquired	Pro Forma
U.S.			
Foot and Ankle	27,727	4,164	31,891
Upper Extremity	4,317		4,317
Biologics	10,685	922	11,607
Other	269	176	445
Total U.S.	42,998	5,262	48,260
International			
Foot and Ankle	7,506	1,511	9,017
Upper Extremity	1,616	477	2,093
Biologics	4,499	27	4,526
Other	1,022	788	1,810
Total International	14,643	2,803	17,446
Global			
Foot and Ankle	35,233	5,675	40,908
Upper Extremity	5,933	477	6,410
Biologics	15,184	949	16,133
Other	1,291	964	2,255
Total Sales	57,641	8,065	65,706

(1) Pro Forma revenues are calculated from adding revenues recognized by Biotech, Solana and OrthoPro prior to our acquisition of these businesses to our reported revenues in each respective period of 2013.

Wright Medical Group, Inc.
Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency
(dollars in thousands--unaudited)

	Three Months Ended		Nine Months Ended	
	September 30, 2014		September 30, 2014	
	International	Total	International	Total
	Net Sales	Net Sales	Net Sales	Net Sales
Net sales, as reported	\$ 20,010	\$ 71,307	\$ 65,142	\$ 214,733
Currency impact as compared to prior period	(117)	(117)	(575)	(575)
Net sales, excluding the impact of foreign currency	\$ 19,893	\$ 71,190	\$ 64,567	\$ 214,158

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	<u>Three Months Ended</u>		<u>Nine Months Ended</u>	
	<u>September 30, 2014</u>	<u>September 30, 2013</u>	<u>September 30, 2014</u>	<u>September 30, 2013</u>
Operating Income				
Operating loss, as reported	\$ (20,649)	\$ (232,559)	\$ (72,866)	\$ (258,966)
<i>Reconciling items impacting Gross Profit:</i>				
Inventory step-up amortization	302	197	1,521	499
BioMimetic inventory write-down	—	979	—	979
Total	302	1,176	1,521	1,478
<i>Reconciling items impacting Selling, General and Administrative expense:</i>				
Distributor conversions	16	112	172	803
Transition costs - OrthoRecon divestiture	879	11,244	4,424	13,867
Due diligence, transaction and transition costs - acquisitions ⁽¹⁾	1,861	1,680	11,606	10,623
Patent dispute settlement	900	—	900	—
Management changes ⁽²⁾	1,203	—	1,203	—
Total	4,859	13,036	18,305	25,293
<i>Reconciling items impacting Amortization of Intangible Assets:</i>				
Amortization of distributor non-competes	462	625	1,526	2,172
<i>Other Reconciling Items:</i>				
BioMimetic impairment charges	\$ —	\$ 206,249	\$ —	\$ 206,249
Operating loss, as adjusted	\$ (15,026)	\$ (11,473)	\$ (51,514)	\$ (23,774)
Operating loss, as adjusted, as a percentage of net sales	(21.1)%	(19.9)%	(24.0)%	(13.6)%

(1) For the nine months ended September 30, 2013, amount includes \$2.3 million of non-cash stock-based compensation expense related to the conversion of BioMimetic options to Wright Medical options.

(2) For the three and nine months ended September 30, 2014, amount includes \$0.3 million of non-cash stock-based compensation expense related to the management changes.

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	Three Months Ended		Nine Months Ended	
	September 30, 2014	September 30, 2013	September 30, 2014	September 30, 2013
EBITDA				
Net loss, as reported	\$ (49,647)	\$ (124,500)	\$ (133,528)	\$ (144,957)
Interest expense, net	4,565	4,044	12,873	11,979
Provision (benefit) for income taxes	3,003	(48,084)	(7,197)	(60,697)
Depreciation	4,654	3,315	13,494	10,264
Amortization of intangible assets	2,379	1,342	7,241	5,726
EBITDA	(35,046)	(163,883)	(107,117)	(177,685)
<i>Reconciling items impacting EBITDA</i>				
Non-cash stock-based compensation expense ⁽¹⁾⁽²⁾	2,586	2,672	8,685	7,177
Other expense (income), net	21,430	(64,019)	54,986	(65,291)
Inventory step-up amortization	302	197	1,521	499
Distributor conversions	16	112	172	803
Due diligence, transaction and transition costs	2,740	12,924	16,030	24,490
BioMimetic impairment and other charges	—	207,228	—	207,228
Patent dispute settlement	900	—	900	—
Management changes	1,203	—	1,203	—
Adjusted EBITDA	\$ (5,869)	\$ (4,769)	\$ (23,620)	\$ (2,779)
Adjusted EBITDA as a percentage of net sales	(8.2)%	(8.3)%	(11.0)%	(1.6)%

(1) For the nine months ended September 30, 2013, amount excludes \$2.3 million of non-cash stock-based compensation expense related to the conversion of BioMimetic options to Wright Medical options, which is included in due diligence, transaction and transition costs.

(2) For the three and nine months ended September 30, 2014, amount excludes \$0.3 million of non-cash stock-based compensation expense related to the management changes, which is included in management changes.

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	<u>Three Months Ended</u>		<u>Nine Months Ended</u>	
	<u>September 30, 2014</u>	<u>September 30, 2013</u>	<u>September 30, 2014</u>	<u>September 30, 2013</u>
Net Income				
Loss before taxes, as reported	\$ (46,644)	\$ (172,584)	\$ (140,725)	\$ (205,654)
<i>Pre-tax impact of reconciling items:</i>				
Inventory step-up amortization	302	197	1,521	499
Distributor conversion and non-competes	478	737	1,698	2,975
Non-cash interest expense on 2017 Convertible Notes	2,333	2,187	6,886	6,456
Derivatives mark-to-market adjustment	1,000	2,000	2,000	3,000
Transition costs - OrthoRecon divestiture	879	11,244	4,424	13,867
Due diligence, transaction and transition costs ⁽¹⁾	1,861	1,680	11,606	10,623
Patent dispute settlement	900	—	900	—
Management changes ⁽²⁾	1,203	—	1,203	—
BioMimetic impairment and other charges and CVR mark-to-market adjustments	18,499	141,081	51,293	146,921
Contingent consideration fair value adjustment	1,750	—	1,750	—
Gain on previously held investment in BioMimetic	—	—	—	(7,798)
Loss before taxes, as adjusted	<u>(17,439)</u>	<u>(13,458)</u>	<u>(57,444)</u>	<u>(29,111)</u>
Provision (benefit) for income taxes, as reported	\$ 3,003	\$ (48,084)	\$ (7,197)	\$ (60,697)
U.S. tax impact resulting from gain in discontinued operations	(2,776)	—	7,940	—
Inventory step-up amortization	—	74	—	192
Distributor conversion and non-competes	—	278	—	1,152
Non-cash interest expense on 2017 Convertible Notes	—	868	—	2,541
Derivatives mark-to-market adjustment	—	781	—	1,181
Transaction and transition costs - OR divestiture	—	4,392	—	5,417
Due diligence, transaction and transition costs	—	468	—	2,471
Patent dispute settlement	—	—	—	—
Management changes	—	—	—	—
Contingent consideration fair value adjustment	—	—	—	—
BioMimetic impairment and other charges and CVR mark-to-market adjustments	—	35,973	—	35,973
Provision (benefit) for income taxes, as adjusted	<u>\$ 227</u>	<u>\$ (5,250)</u>	<u>\$ 743</u>	<u>\$ (11,770)</u>
Effective tax rate, as adjusted	<u>(1.3)%</u>	<u>39.0%</u>	<u>(1.3)%</u>	<u>40.4%</u>
Net loss, as adjusted	<u>\$ (17,666)</u>	<u>\$ (8,208)</u>	<u>\$ (58,187)</u>	<u>\$ (17,341)</u>
Weighted-average number of shares outstanding-diluted	50,043	46,418	49,441	44,721
Net loss from continuing operations, as adjusted, per diluted share	<u>\$ (0.35)</u>	<u>\$ (0.18)</u>	<u>\$ (1.18)</u>	<u>\$ (0.39)</u>

(1) For the nine months ended September 30, 2013, amount includes \$2.3 million of non-cash stock-based compensation expense related to the conversion of BioMimetic options to Wright Medical options.

(2) For the three and nine months ended September 30, 2014, amount includes \$0.3 million of non-cash stock-based compensation expense related to the management changes.

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(continued)

	Three Months Ended		Nine Months Ended	
	September 30, 2014	September 30, 2013	September 30, 2014	September 30, 2013
Net Income per Diluted Share				
Net loss from continuing operations, as reported, per diluted share	\$ (0.99)	\$ (2.68)	\$ (2.70)	\$ (3.24)
U.S. tax impact resulting from gain in discontinued operations	0.06	—	(0.16)	—
Inventory step-up amortization	0.01	0.00	0.03	0.01
Distributor conversion and non-competes	0.01	0.01	0.03	0.04
Non-cash interest expense on 2017 Convertible Notes	0.05	0.03	0.14	0.09
Derivatives mark-to-market adjustment	0.02	0.03	0.04	0.04
CVR mark-to-market adjustments	0.37	2.25	1.04	2.47
Transition costs - OrthoRecon divestiture	0.02	0.15	0.09	0.19
Due diligence, transaction and transition costs	0.04	0.03	0.23	0.18
Patent dispute settlement	0.02	—	0.02	—
Management changes	0.02	—	0.02	—
Contingent consideration fair value adjustment	0.03	—	0.04	—
Gain on previously held investment in BioMimetic	—	—	—	(0.17)
Net loss from continuing operations, as adjusted, per diluted share ⁽¹⁾	\$ (0.35)	\$ (0.18)	\$ (1.18)	\$ (0.39)

(1) Reconciling items may not add to total net income, as adjusted, per diluted share due to rounding differences.

Wright Medical Group, Inc.
Reconciliation of Free Cash Flow
(dollars in thousands--unaudited)

	Three Months Ended		Nine Months Ended	
	September 30, 2014	September 30, 2013	September 30, 2014	September 30, 2013
Net cash used in operating activities	\$ (34,562)	\$ (34)	\$ (86,152)	\$ 5,721
Capital expenditures	(11,422)	(12,777)	(35,706)	(22,512)
Free cash flow	\$ (45,984)	\$ (12,811)	\$ (121,858)	\$ (16,791)